Thursday 14thNovember

The Royal Institution 21Albemarle Street, Mayfair London presented by longevity, beyond the have thepower to effect change. Thisis also audiences of this Forum and the promotion the reason why the Forum decided to host of a positive agenda around longevity, is its first Longevity Week as an extension of critical. the mission of the Forum, and we thank all the global strategic partners and supporters We believe that in the next decade there who made this possible. is the potential for a step change in both the policy and attitudes which are required The Global Agenda, one of the Forumʼs LONGEVITY 2030 for societies to reap a significant longevity flagshipinitiatives developed in conjunction dividend and maximise the return on with the Stanford Center on Longevity and The Next Ten Years longevity. launched at a Longevity Week event in Singapore earlier this week, embodies the This is why the theme of this yearʼs Forum global nature of the opportunities at hand. and Longevity Week is Longevity 2030 – a It follows a high-level meeting of experts deeper dive into the ideas and innovations co-hosted by The Longevity Forum earlier that will shape humanity in the next 10years. this year around the concept of ʻA New Welcome to The Longevity Forum Our agenda is ambitious,but it matches the Map of Lifeʼ. This initiative outlined the level of change that we expect to see over principles which make longevity distinct 2019,our second annual Forum the next decade. Already we can see how from and set high level objectives the longevity agenda is advancing in the which governments around the world need and the closing event of our first UK on many fronts. to achieve in the next 10 years to support the longevity agenda. Longevity Week. This yearʼs Forum will explore the ever- expanding boundaries of science and Following last yearʼs Forum, we also technology; the economic opportunities decided, with your help, to launch two presented by longevity and implications key initiatives related to the mission of the for governments and individuals; the Forum. These were supporting research policy agenda supporting our educational, into scleroderma, a rare autoimmune healthcare and social care systems to disease, by leveraging Insilico Medicineʼs ensure they are fit for the future; a look next generation , and at what is happening internationally; and, launching the Encore Fellows Scheme in Jim Mellon, Dafina Grapci-Penneyand Andrew Scott lastly,the relationship between humansand the UK to mentor retirees into new roles. Founders, The Longevity Forum machines and the governance framework We are excited about the progress made needed to ensure that this growing inter- in both areas and look forward to reporting dependence can help humans achieve this back to you as well as announce our When we set up the Forum,just over a year way for their implementation through our their full potential. 2020 projects. ago, our main objective was to facilitate the network of partners across diverse sectors exchange of ideas between experts from and countries. This approach remains core As ever, the quality of the speakers and As Longevity 2030, the theme of this the fields of science and social science to to our mission -which is to promote happier, the audience we have attracted this year yearʼs events attests, we are committed to explore the opportunities presented by healthier and more fulfilled lives for as many reflects the convening power of the Forum this mission for the long term and we are increases in humanlongevity. people as possible. across the worlds of government, business, excited about the opportunity to amplify the finance, research, academia and of NGOs. missionof the Forumthroughnew ideas and Our vision was to create a forum where To achieve this mission, the Forum aims to It is this growing network of individuals partnerships. We look forward to building cutting edge ideas would be generated, make these ideas accessible to all. This is and organisations whose interests are fully on the foundations of this weekʼs events debated and critiqued, thus paving the why raising awareness of the opportunities aligned with the goals of our mission that and continuing to foster such collaboration.

www.thelongevityforum.com The Longevity Forum 2019 10.25 -10.50 Age Before Beauty? Examiningthe False Auditorium Dichotomy of Lifespan Versus Healthspan

Dr Nir Barzilai PROGRAMME Founding Director, Institute for Aging at The Albert Ein- stein College of Medicine

Aubrey de Grey Chief Science Officer of the SENS Research OF EVENTS Foundation

Laura Deming Founder, The Longevity Fund 08.30 -09.00 Registration & Coffee The Grand Entrance 10.50 -11.20 Coffee Break The Library and Georgian Room 09.00 -09.15 Longevity 2030 -The Next Ten Years Auditorium

Jim Mellon 11.20 -12.05 Panel: How Can the UK Add Five Years of Healthy Auditorium Co-Founder,The Longevity Forum Lifespan by 2030?

Professor Andrew Scott Dr Charles Alessi Co-Founder,The Longevity Forum Chief Clinical Officer, HIMSS International Professor Lynne Cox Professor of Biochemistry, Oxford University 09.15-09.20 Beyond 100(video) Auditorium Tina Woods Barclays Private Bank CEO and Co-Founder,Longevity International

Moderated by 09.20 -09.35 Keynote: Scientists, check. Investors, check. Auditorium Greg Bailey, MD Next up, policy-makers CEO, Juvenescence Limited

Aubrey de Grey Chief Science Officer of the SENS Research Foundation 12.05 -13.00 Panel: Technologies shaping the future of humanity Auditorium over the next decade

09.35 -09.50 Keynote: Investing in Human Longevity Auditorium Camilla Cavendish, Baroness Cavendish of Little Venice Author of “Extra Time: Ten Lessons for an Ageing World” Founder, The Longevity Fund Professor Stephen Emmott Founder and CEO, Scientific Auditorium 09.50 -09.55 The Longevity Forum Projects: Scleroderma & James Lawford Davies Raynaudʼs UK Partner, Hill Dickinson LLP

Polina Mamoshina Dr Ali Parsa Head of Biomarker Development, Insilico Medicine Founder and CEO, Babylon Health

Anders Sandberg 09.55 -10.25 Keynote: How to Die Youngat a Very Old Age Auditorium Senior Research Fellow, Future of Humanity Institute, University of Oxford Dr Nir Barzilai Moderated by: Founding Director, Institute for Aging at The Albert Dafina Grapci-Penney Einstein College of Medicine Co-Founder,The Longevity Forum

www.thelongevityforum.com The Longevity Forum 2019 Presentation: Bloomberg 2019Healthiest Country 13:00 -14.00 Lunch The Library/Georgian 16.20 -16.35 Auditorium Room Index Scott Johnson Economist, Bloomberg Economics 14:00 -14.30 Keynote: Realising the Opportunities of Longer Auditorium Lives Presentation: Working Together as We Work Longer: Auditorium Dr Linda P. Fried 16.35 -16.55 A Framework for Collaboration to Benefit from Lon- Dean, Mailman School of Public Health, Columbia gevity University Cynthia Brown Vice President, Operations & Finance, AARP 14.30 -14.35 The Longevity Forum Projects: Encore Fellows Auditorium UK 16.55 -17.15 Presentation: Age -the Grand Challenge Auditorium Julia Randell-Khan Senior Fellow, Encore.org Andy Briggs Co-Chair,UK Longevity Council

14.35 -14.40 Presentation: The Global Initiative Auditorium

Joseph F. Coughlin Auditorium Director, the Massachusetts Institute of 17.15 -17.30 Closing Remarks: The Longevity Forum and Technology AgeLab Longevity Week

Professor Andrew Scott, Dafina Grapci-Penney, 14.40 -15.40 The Longevity Dividend Panel Auditorium Jim Mellon

Cynthia Brown 17.30 Drinks Reception The Library Vice President, Operations & Finance, AARP

Professor David Miles, CBE Imperial College, London Gerald Moser Slido Chief Market Strategist, Barclays Private Bank

Yvonne Sonsino Today, we will be using Slido to collect To register, go to slido.com on your phone Partner and Innovation Leader, Mercer questions and allow you to express your or download the app and type in code opinion in live polls. #longevityor use the QR Code below. Moderated by: Professor Andrew Scott Co-Founder,The Longevity Forum

15.40 -16.10 Afternoon Break The Library/Georgian Room Join at

16.10-16.20 Report: The Global Longevity Agenda Auditorium slido.com

Professor Andrew Scott Co-Founder,The Longevity Forum #longevity

www.thelongevityforum.com The Longevity Forum 2019 FOUNDERSOFTHELONGEVITYFORUM

Andrew Scott

Andrew Scott is Professor of Economics at London Business School and a Fellow of All Souls, Oxford University andtheCentre for Economic Policy Research. He previously held lecturing positions at Harvard University, FOUNDERS London School of Economics OF THE and University of Oxford.

LONGEVITY Andrewʼsresearch focuses onthe economics our lives. He is currently investigating an of longevity and how individuals, corporates economic longevity dividend withthe support and governments need to adapt to seize of a £1mnESRC grant. FORUM the opportunities of long and healthier lives. Andrewʼs 2016 book “The 100 Year Life” He is a member of the advisory board of the on this theme was an award winning global UKʼs Office for Budget Responsibility and the best seller, translated into 15languages. His Cabinet Office Honours Committee (Science next book, ”A New Long Life”, is out in May and Technology)having previously served as 2020 and will look at how the twin forces of Non-Executive Director of the UKs Financial technology and longevity are set to change Services Authority 2009-13.

TheThe Longevity Longevity ForumForum 2019 2019 FOUNDERSOFTHELONGEVITYFORUM FOUNDERSOFTHELONGEVITYFORUM

Jim Mellon Dafina Grapci-Penney

Jim is a British entrepreneur and Dafina Grapci-Penney is a Trustee investor with a wide range of of The Longevity Forum. She interests. Through his private is also a Managing Director at investment company, Burnbrae Greentarget, a communications Group, he has substantial real consultancy advising global estate holdings in Germany and financial institutions and the Isle of Man, aswell asholdings corporates. in public and private companies.

Jimʼs investment philosophy is underpinned Jim and his partners have now set up Dafina works with firms operating at the On behalf of the Longevity Forum, Dafina by his ability to recognise emerging trends Juvenescence Limited,a company developing cutting edge of finance and technology works to develop partnerships with a wide that give rise to new industries or major shifts therapies forageing and the diseases ofageing. on their communications strategies with range of external stakeholders, including in markets. This includes the global financial a wide range of stakeholders. She has a financial institutions and corporates, crisis of 2008-2009, as foreseen in the first Jim sits on the Board of Trustees of the Buck deep understanding of global drivers and governments, public policy bodies and book Jim co-authored entitled Wake Up!, Institute for Research on Aging, and the macro trends that influence how businesses foundations with a view to helping shape and subsequently in the new science and American Federation for Aging Research operate and prepare for the future. the agenda of the Forum and amplifying its technologies detailed in Cracking the Code (AFAR). He is also a trustee of mission. and Fast Forward. Research Foundation and Lifeboat Foundation, Dafina is particularly interested in the trends is an Honorary Fellow of Oriel College at the shaping the future of humanity and the role Dafina began her career in communications More recently Jim has established himselfas University of Oxford and sits on the Advisory that technology, businesses and policy can with NATOʼs peacekeeping operation in the a thoughtleader inthe nascent fieldof ageing Board of the Milken Instituteʼs Centre for the play to influence positive outcomes for Balkans, followed by roles in the financial research and longevity. His groundwork Future of Aging. Jim has been honoured by individuals and the society. practice of Weber Shandwick, a global public into the field is summarised in the book AFAR with the George E. and Marie J. Doty relations firm. Juvenescence which he also co-authored. Award for his supportof ageing research.

www.thelongevityforum.com The Longevity Forum 2019 KEYNOTESPEAKERS

Nir Barzilai

Dr Barzilai is a chaired Professor of Medicine and and Director of the biggest Centre in the world to study the Biology of Ageing, Institute for Aging at The Albert Einstein College of Medicine. He is the recipient of an NIH Merit Award aiming to extend KEYNOTE the healthy life span of rodents by SPEAKERS biological interventions. He also studies families of centenarians that He is a founder of CohBar Inc (now a public have provided genetic/biological insights company) and Medical Advisor for Life on the protection against ageing. Several Biosciences. He is the Co-Scientific Director drugs are developed and based, in part, on of the American Federation ofAging Research these paradigm-changing studies. He is a as well as being on the board of AFAR and recipient of numerous prestigious awards, CohBar. He has been featured in major including the 2010 Irving S Wright Award of papers, TV programmes and documentaries Distinction in Aging Research and is the 2018 (TEDx and TEDMED) and has presented the recipient of the IPSEN Longevity Award. He promise for targeting ageing at The Singapore is leading the TAME (Targeting/Tamingaging Prime Minister Office, several International with Metformin) multicentral study to prove Banks, The Vatican, Pepsico, Milken Institute, the concept that multi morbidities of ageing the Economist and Wired Magazine. can be delayed in humansand to change the FDA indications to allow for next generation interventions.

The Longevity Forum 2019 KEYNOTESPEAKERS KEYNOTESPEAKERS

Laura Deming Linda P. Fried

Laura Deming is the founder and Linda Fried is Dean and DeLamar full-time partner at The Longevity Professor of Public Health at Fund, an early stage venture Columbia Universityʼs Mailman capital fund backing companies School of Public Health. A world- which target the ageing process renowned geriatrician and to treat disease, with investments epidemiologist, Dr. Fried is a serial in gene editing, small molecule innovator, known for tackling the therapeutics, and novel methods major issues of our lengthening to treat disease. lives.

From a young age, Ms. Deming has been Laura matriculated at Massachusetts Institute Her scientific contributions include creating University Mailman School has developed fascinated by the idea that longevity is a of Technology (MIT) at age 14. At MIT she the transformational science defining frailty as new dimensions of public health science, from mechanism able to be manipulated. After worked on artificial organogenesis and bone a medical condition; research on the natural the University-wide Robert N. Butler Columbia years working on nematode longevity at ageing. She is now based in San Francisco, history of frailty and disability; and illuminating Aging Center to the new science of precision the University of California, San Francisco working to find and fund therapies to extend their causes and the potential for prevention prevention, and has become a key leader in in the lab of Dr. , molecular the human healthspan. and treatment as keys to optimizing health for innovation in public health education and in biologist known for her research on ageing, older adults. She is the designer and founder intersectoral partnerships for health. of Experience Corps, an evidence-based senior volunteer program in which older adults Dean Fried was named one of the 1% most serve in public schools. The program was influential scientific minds of the past decade found to simultaneously prevent cognitive loss in 2014 by Thomson . She is an and functional decline in the volunteers while elected member of the US National Academy benefiting students. Dean Fried advocates for of Medicine, and of its executive Council. In the potential of longer lives to be the basis of a 2016-17she served as the President of the Third Demographic Dividend whereby society Association of American Physicians. The benefits from the social capital of older adults recipient of numerous awards and prizes, and invests in health promotion across the life she received the French National INSERM course. Under her leadership, the Columbia International Prize in Medical Research in 2017.

www.thelongevityforum.com The Longevity Forum 2019 KEYNOTESPEAKERS

Aubrey De Grey

Dr Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California- based501(c)(3)biomedical research charity that performs and funds laboratory research dedicated to combating the ageing process. PRESENTERS

He is also VP of New Technology Discovery constitute mammalian ageing and the design at AgeX Therapeutics, a biotechnology start of interventions to repair and/or obviate that up developing new therapies in the field of damage. Dr de Grey is a Fellow of both the biomedical . In addition, he is Gerontological Society of America and the Editor-in-Chief of Research, American Aging Association, and sits on the the worldʼs highest-impact peer-reviewed editorial and scientific advisory boards of journal focused on intervention in ageing. numerous journals and organisations. He is a He received his BA in computer science highly sought-after speaker who gives 40-50 and Ph.D. in biology from the University of invited talks per year at scientificconferences, Cambridge.His research interests encompass universities, companies in areas ranging from the characterisation of all the types of self- pharma to life insurance, and to the public. inflicted cellular and molecular damage that

www.thelongevityforum.com The Longevity Forum 2019 PRESENTERS PRESENTERS

Andy Briggs Cynthia Brown

Andy was most recently CEO of Cynthia Brown is Vice President Aviva UK Insurance and was on for Operations & Finance in the the Aviva plc Board. Prior to that Office of the Chief Operating he wasGroup CEO of FriendsLife. Officer at AARP, the USAʼs largest nonprofit, nonpartisanorganization dedicated to empowering people to choose how they live asthey age.

He has over 25 years of operational and He has extensive knowledge of the UK With 38 million members and offices in every consumer health products and services arena. executive experience in the insurance regulated environment combined with state and territory, AARP works to strengthen In addition, she provides strategic leadership to industry across life assurance and general experience in capital and risk management. communities and advocate for what matters the nationally and internationally focused AARP insurance, both in the UK and overseas. Andy was formerly CEO of Scottish Widows mostto families – with a focus on health security, Brain Health Fund which provided a $60 million plc (financial services), CEO of the General financial stability,and personal fulfillment. With investment in theLondon-based Dementia At Friends Life he led the transformation of Insurance businesses of Lloyds Banking keenawareness ofthe longevityeconomy,AARP Discovery Fund lastyear designed to accelerate the three acquired businesses and brings his Group plc (financial services) and CEO of also works for individuals in the marketplace by research into cures for all types of dementia strategic and business skills, experience of the Prudential Groupʼs Retirement Income sparking new, innovative solutions and allowing includingAlzheimerʼs. organisational change and knowledge of the business (insurance). carefully chosen products and services to carry Friends Life business to the board. the AARP name. During her tenure at AARP, Brown has led the centralization of AARPʼs financial functions, Cynthia manages and executes on a broad resulting in enhanced strategic decision range of strategic finance and operations issues support to executive management, played a ensuring effective integration, coordination and key role in improving customer service and communicationacross theenterprise.A primary reducingoperationalcosts,and transformedthe focus of her work is on AARPʼs social impact organizationʼs financial planning and analysis investment strategy. She oversees the AARP function byshiftingfocusfromannualbudgeting Innovation Fund, a $40 million venture capital to strategic business and financial planning, and investment vehicle to spur innovation in the new business opportunityassessment.

www.thelongevityforum.com The Longevity Forum 2019 PRESENTERS PRESENTERS

Joseph Coughlin Scott Johnson

Joseph Coughlin is the founder Scott Johnson is an economist with and director of the MIT AgeLab, Bloomberg Economics in London, a multi-disciplinary research where he writes research on Russia program created to understand and broader trends in emerging the behaviour of the 50+ markets. population,the role of technology in their lives,and the opportunity for innovation to improve the quality of life for older adults and their families.

He is a member of the board of directors market: a vast, diverse group of consumers A former journalist, he previously edited Kong, with a focus on institutional investors of AARP, AARP Services, and Benchmark representingevery possiblelevel ofhealthand Bloombergʼs economic research and daily and retail funds.He began hiscareer reporting Senior Living. Coughlin consults with wealth, worth about $8 trillion in the United newsletters inEurope andAsia. Prior tothat,he on local politics in the U.S. Southwest. He has major companies in the United States and States alone and climbing.Coughlin pinpoints reported on asset management for Financial a B.A. in Economics and Environmental Policy internationally, including BMW, Colgate, the gap between myth and reality and then Times publications in New York and Hong from the College of William and Mary. Kimberly Clark, JP Morgan, Marriott,Johnson shows businesses how to bridge it. As the & Johnson, Cartier, and many others. demographics of global ageing transformand accelerate, it is now critical to build a new In his book The Longevity Economy, Coughlin understanding of the shifting physiological, provides the framing and insight business cognitive, social, family, and psychological leaders need to serve the growing older realities of the longevity economy.

www.thelongevityforum.com The Longevity Forum 2019 PRESENTERS PRESENTERS

Polina Mamoshina Julia Randell-Khan

Polina is Head of Biomarker As founder and CEO of Encore Development at Insilico Fellows UK, Julia is an enthusiastic Medicine, Inc, a Baltimore-based encore career advocate. Finding bioinformatics and deep learning no road map for her own transition company focused on reinventing from along-termcareerin the legal drug discovery and biomarker field (atNorton Rose Fulbright and development and a part of the Freshfields Bruckhaus Deringer), computational biology team of Julia decided to create one. Oxford University Computer Science Department.

Insilico Medicine, Inc is headquartered at responses, healthcare data management, This led Julia to Stanford Universityʼs transition to retirement. Julia combines this the Johns Hopkins University -Montgomery and healthcare data economy. Distinguished Careers Institute combined with her on-going fellowship at Stanford County Campus in Rockville. The company with a role at Encore.org, the leading non- Universityʼs Center on Longevity working on is focusing on applying deep learning and Polina graduated from the Department of profitin the encore movement, which taps the the New Map of Life project. advanced signalling pathway activation Genetics of the Moscow State University. skills and experience of those in midlife and analysis to biomarker discovery, drug She was one of the winners of GeneHack beyond for social change. At Encore.org Julia Julia is an active mentorand worksclosely with discovery and drug repurposing for ageing a Russian nationwide 48-hour hackathon works on building global and cross-cultural Fair Trials,a specialist human rights NGO. She and age-related diseases. Through a on bioinformatics at the Moscow Institute of connections. This includes leading the Encore also set up a network, Women in Transition, partnership with the BitFury Group, the Physics and Technologyattended by hundreds Fellows UK programme which draws on the to support growth and development from company is working on a range of AI of young bioinformaticians. She is involved successful US scheme to offer experienced change as senior women transition from long solutions for blockchain to help return the in multiple deep learning projects at the talent an opportunity to work on a paid, high term careers to new opportunities in the next power over life data back to the individual. Pharmaceutical Artificial Intelligence division impact assignment as part of purposeful phase of life. A brief video explaining Insilico Medicine of Insilico Medicine working on the drug research and commercial focus is available discovery engine and developing biochemistry, on Youtube. Her primary research interests transcriptome, and cell-free nucleic acid-based include artificial intelligence, deep learning, biomarkers of ageing and disease. biomarkers of ageing and disease and drug

www.thelongevityforum.com The Longevity Forum 2019 SCIENCEPANEL

Charles Alessi

Charles Alessi is the Chief Clinical Officer for HIMSS International. HIMSS is a global voice, advisor and thought leader of health SCIENCE PANEL transformation through health information and technology with a unique breadth and depth of W hat does the UK need to ensure expertise and capabilities to improve that we add 5 more years of healthy the quality, safety, and efficiency of health, healthcare and care outcomes. life for everyone by 2030? As Chief ClinicalOfficer forHIMSS International, at the Schulich School of Medicine for the Alessi leads relationship-buildingeffortsamong University of Western Ontario, Canada, and as This panel will explore the recent advances be malleable, make the bioengineering HIMSSʼs various international clinician-focused executive director of the Global International in pro-longevity therapies, including of human beings to live longer and more communities; furthering HIMSSʼs position as Care Delivery Alliance. small molecules, stem cells, regenerative robustly a strong likelihood, rather than an a thought leader in the health industry and medicine, microbiome and . historically improbable aspiration. Indeed, it supporting both the vision and understanding Alessi is also the senior advisor for Public All of these are, to varying degrees, in is clear that the science of biogerontology is of information and technologyʼs roles in the Health England, leading national policy human trials and the combination of these rapidly catching up with the desire of most of advancement of health and care. implementation, productive healthy ageing exciting developments and the fact that us to live longer and in better health. and is currently contributingto the global World ageing pathways have been proven to Before joiningHIMSS in 2018,Alessi has acted Health Organization guidelines for dementia innumerousexternal positions forgovernments risk reduction. Alessi has also contributed his and executive agencies on a national and expertise to multiple international publications Panel moderated by international level. Alessi brings more than such as the BritishJournal of General Practice, 25 years of experience in global healthcare addressing topics such as health and social policy and clinical practice to HIMSS. Most care contractand health policy.He has lectured recently, he chaired the National Association of and led keynote addresses for healthcare Greg Bailey, MD Primary Care (NAPC), has served as an adjunct engagements taking place on every continent research professor for Clinical Neurosciences (except Antarctica).

The Longevity Forum 2019 SCIENCEPANEL SCIENCEPANEL

Lynne Cox Tina Woods

Professor Cox is a biogerontologist Tina WoodsisCEO andFounderof at the University of Oxford. She Collider Health,a healthinnovation runs a research group focused on catalystworking with organisations understanding the basicmolecular in both private and public sectors mechanisms underlying ageing, (corporates, investors, third sector, with the aim of using that government, SMEs and start-ups) understandingto improve healthin to accelerate innovation. later life, by developing treatments to alleviate the diseasesof old age.

She received her MA and PhD in Natural of Biology, and co-founderofthe OxfordAgeing Tina is an ecosystem architect and builds Innovation. Tina is also CEO and Co-founderof Sciences at the , Network, OxAgeN, which now formspart of the collaborative networks and strategic Longevity International, which runs the All-Party then carried out post-doctoral work on the wider Oxford collaboration on ageing. In 2015, partnerships to transform health with Parliamentary Group for Longevity, developing tumour suppressor p53 in Dundee with Prof she received the US Glenn Foundationaward, sustainable impact at scale. Tina and her a UK National Strategy to help deliver 5 extra Sir David Lane. She was awarded a Royal presented at the House of Lords, for research team at Collider Health work with NHS X and years ofhealthylifeexpectancy toallUK citizens Society of Edinburgh Research Fellowship into the biological mechanisms of ageing. She the National AHSN Network to build the AI by 2035 while closing the social gap to ensure to progress her independent research, and serves on the All-PartyParliamentary Group on ecosystemfor theNHS, with AXA healthinsurer democratic access to the ʻlongevity dividendʼ. from this, developed initial IP for the spin-out Longevity, the Clinical and Translational theme on their corporate innovation programme Tinais also CEO &Founder of ColliderScience, Cyclacel (https://www.cyclacel.com).She holds panel of the Biochemical Society, is a primary Health Tech & You. that aims to inspire young people in science a Fellowship at Oriel College, Oxford, and an international member of the Norwegian NO- and technology and equip them with the skills Associate Professorship at the Department of Age consortium,and has justbeen elected co- She has been involved in consortia for the future. Tina writes regularly for Forbes, Biochemistry, University of Oxford. chair of a new EU special interest group of the development for the Healthy Ageing Industrial D/sruption and other media channels, and is European Geriatric Medicine Society on the Strategy Challenge Fund with UK Research & currently writing a book, ʻLive Longer with AIʼ. She is a Trustee of the British Society for biology of ageing. Research onAgeing,Fellow ofthe RoyalSociety

www.thelongevityforum.com The Longevity Forum 2019 SCIENCEPANELMODERATOR

Greg Bailey

Dr Bailey is the CEO of Juvenescence Limited a company that develops therapeutics,sopeople can live longer, healthy. Juvenescence develops drugs, IP protected consumer products and TECHNOLOGY PANEL other therapeutic modalities to slow ageingand increase a healthy lifespan. The company usesAI to augment its Technologies Shaping drugdiscovery and drugdevelopment the Future of Humanity programmes in partnership with Insilico Medicine and NetraMark.

Dr Bailey has been founding and financing Gregory Bailey currently sits on the board life science companies since 1995. Some of of directors of 3 public companies: Portage Technology has accelerated the pace of editing to eliminate disease and the rise of these companies have traded on NASDAQ, Biotech, Inc.; SalvaRx PLC.; and Biohaven innovation and this presents significant super intelligence as we witness the merging AIM, AMEX and the NYSE, reaching over $19 Pharmaceutical Holding Company Ltd.SalvaRx opportunities to help promote longer, of humans and machines will present both billion in market capitalization. He co-founded is an Immune-oncologycompany which went healthier and more fulfilled lives. A number opportunities and challenges. The panel will Ascent Health Care in 1995 it was sold to public in February 2016. Portage was the of technologies and innovations have the debate the optimal governance framework Stryker for $525 million and he financed major shareholder in Biohaven beginning in potential to shape the future of humanity required to ensure that these technologies Medivation Inc., (MDVN: NASDAQ) with $14 January 2014untila dividend of $200 millionof over the next decade. The use of robots and innovations can help society fulfil its million at a $12million pre-money. Medivation Biohaven shares to its shareholders. Dr Bailey in social care, the application of artificial potential rather than create inequality. was acquired by Pfizer in September 2016for remainsamajorshareholder ofBiohaven which intelligence in healthcare, the role of gene $14.3billion. In January 2014 Declan Doogan went public in May 2017and has a market cap and Dr Bailey capitalized Biohaven through of a little over $2.4 billion. Portage with 3.5 million for 54% and added a further $3.5 million over the next 2 years. That Dr Bailey received his medical doctorate from Panel moderated by position in Biohaven is now worth$400 million. University of Western Ontario. Dafina Grapci-Penney (Biography in founders section)

www.thelongevityforum.com The Longevity Forum 2019 TECHNOLOGYPANEL TECHNOLOGYPANEL

Camilla Cavendish StephenEmmott

Camilla Cavendish is an Stephen is a scientist and award-winning journalist and entrepreneur with a track record broadcaster, and the author of of scientific leadership and “Extra Time: Ten Lessons for technological innovation in some an Ageing World”, published of the worldʼs leading technology by HarperCollins in 2019. She companies.He is Founder and CEO is a Senior Fellow at Harvardʼs of Scientific, a technology business Kennedy School. which operates at the intersection of science, technology and impact investment innovation.

She is also ContributingEditor at the Financial Camillaʼs work has changed the law: her From 2003 to 2016, Stephen was Chief Stephen is also Professor of Biological Times where she writes a weekly op-ed exposure of miscarriages of justice in family Scientist and Global Head of Computational Computation at University College column on Saturdays. courts led the Brown government to open Science at Microsoft,where he led Microsoftʼs London and was previously Professor of those courts to the media in 2009. Her awards Computational Science Laboratory in Computational Science at the University Camilla was Head of the Prime Ministerʼs UK include Wincott Senior Financial Journalist Cambridge, pioneering new kinds of science of Oxford (2007-2014). He was scientific Policy Unit under David Cameron. One of of the year, and the Paul Foot award for to develop previously impossible, game- advisor to the Chancellor of the Exchequer the policies associated with her is the 2016 investigative journalism. changing solutions to this centuryʼs greatest (2005-2010). In 2012 his 10 Billion lecture “sugar tax” on fizzy drinks. She has been a challenges and opportunities. Prior to that, at The Royal Court Theatre received critical Non-Executive Director of the Care Quality Camilla began her career at McKinsey & Co. Stephen and was Chief Scientist, NCR acclaim. 10Billion was published as a book Commission, and was author of the 2013 She helped to found the lobby group London Corporationʼs Advanced Research Lab. in 2013 and became an international best- Cavendish Review, an independent review Firstandwas CEO oftheSouthBank Employersʼ Stephen started his career as a postdoctoral selling book. In 2015, 10 Billion was made for the Department of Health, into junior Group, a public-private joint venture which scientist at Bell Laboratories, under Nobel into a feature-length documentary film. nursing staff and care workers. She now sits regenerated parts of Londonʼs south bank. Laureate Arno Penzias. in the House of Lords as a non-aligned peer: She holds degrees from Oxford and Harvard Baroness Cavendish of Little Venice. and chairs the non-profitFrontline, which puts talented graduates into social work.

www.thelongevityforum.com The Longevity Forum 2019 TECHNOLOGYPANEL TECHNOLOGYPANEL

James Lawford Davies Ali Parsa

James is a solicitor and partner at Hill Dr Ali Parsa is a British-Iranian Dickinson in London. He specialises healthcare entrepreneur and in life sciences regulation and engineer. litigation with a particular interest in cell and gene therapies. He advises a large number of companies, clinics, and universities regulated by the MHRA, HFEA andHTA, andhasbeen involved in most of the leading cases relating to reproductive and genetic technologiesin the UK.

He advised the Francis Crick Institute in James was previously a lecturer at the Heʼs the founder and CEO of Babylon, the him as one of ʻthe 50 most influential people relation to their successful application to use Institute of Human Genetics at the University revolutionary AI and digital health company. in UK healthcareʼ. He was featured in the germline genome editing in human embryos, of Newcastle, a Visiting Research Fellow at Babylonʼs mission is to put an accessible and Maserati 100, a list that recognises game- the first such regulatory approval of its kind Durham University Law School, and is now affordable health service in the hands of every changing entrepreneurs. Heʼs a UK Cabinet in the world. In addition, he advised the an Honorary Lecturer in the Department of person on earth. Office Ambassador for Mutuals and has a PhD Wellcome Trust and Newcastle University in Biochemical Engineering at UCL. in Engineering Physics. relation to mitochondrial donation, both as a Dr Parsa was listed in The Times 100people to research project and therapy, and in relation James contributed a chapter (The Regulation watch. The Health Service Journal recognised to the successful passage of the draft Human of Human Germline Genome Modification Fertilisation and Embryology (Mitochondrial in the United Kingdom) to a new Cambridge Donation) Regulations 2015 (a similar route University Press textbook on genome editing to that required to allow the use of genome which will be published in January 2020. editing in therapy).

www.thelongevityforum.com The Longevity Forum 2019 TECHNOLOGYPANEL

Anders Sandberg

Andersʼ research at the Future of Humanity Institute centres on management of low-probability high-impact risks, estimating the capabilitiesoffuturetechnologies, THE LONGEVITY and very long-range futures DIVIDEND PANEL

With 80% of employment growth in the wake up to the needs of an older workforce US, UK, Germany and Japan in the last 20 and realising the potential for new products years coming from those aged over 65; should we start talking more about the Anders is a Senior Research Fellow on the ERC He is on the advisory boards of a number of with growing VC investment in life sciences longevity dividend rather than the silver UnPrEDICT Programme and the FHI-Amlin organisations and often debates science and focusing on ageing; with firmsbeginning to tsunami of an ageing society? Collaboration. Topics of particular interest ethics in international media. Anders has a include global catastrophic risk, cognitive backgroundincomputerscience,neuroscience biases, cognitive enhancement, collective and medical engineering. He obtained his intelligence, neuroethics, and public policy. Ph.D. in computational neuroscience from He is research associate to the Oxford Uehiro Stockholm University, Sweden, for work on Centre for Practical Ethics, and the Oxford neural network modelling of human memory. Panel also includes Centre for Neuroethics. Cynthia Brown (Biography in the Presenters section)

PanelPanelmoderatedmoderatedbyby

AndrewCynthiaScott Brown (Biography(Biographyin Longevity in the Forum presentersfounders section)section)

www.thelongevityforum.com The Longevity Forum 2019 THELONGEVITYDIVIDENDPANEL THELONGEVITYDIVIDENDPANEL

David Miles, CBE Gerald Moser

David Miles is Professor of Gerald joined Barclays in 2019 Financial Economics at Imperial as Chief Market Strategist. In College, London. He was a this position, he is responsible member of the Monetary Policy for Barclays Private Bank and Committee at the Bank of Overseas Services investment England between May 2009 and views. September 2015.

With his team, he defines the advisory worked for almost a decade in the Global As an economist he has focused on the He is a research fellow of the Centre for investment views through thematic and Investment Research division at Goldman interaction between financial markets and the Economic Policy Research and at the CESIFO opportunistic investment ideas while also Sachs as a strategist, providing investment wider economy. He was Chief UK Economist research institute in Munich. He is Chair of contributing inputs to the discretionary ideas to a broad set of institutionalclients. at Morgan Stanley from October 2004 to May the Board of Trustees of the Institute for Fiscal process. Prior to his appointment at Barclays, 2009. Studies. Gerald spent several years at Credit Suisse Gerald graduated from Paris Dauphine in its Wealth Management division where he University with a MSc in International In 2004 he led a government review of the UK He was awarded a CBE in January 2016. was in charge of the equity views as well as Management. mortgage market. He recently completed a thematic investment ideas. Prior to that he review for the UK Treasuryon reference prices of UK government bonds. He is an advisor to the IMF.

www.thelongevityforum.com The Longevity Forum 2019 THELONGEVITYDIVIDENDPANEL

Yvonne Sonsino

Yvonne re-joined Mercer in 2013, after six years out of the consulting industry working in senior HR roles in the Middle East and Europe. In her previous role in Mercer, Yvonne led the International Consulting Group in London, working with global companies on HR policy and STRATEGIC PARTNERS programme design.

Prior to that, there were a further fifteen from the UK Pensions Minister. She is also years in the HR consulting industry. Her working on Mercerʼs answer to the Mid-Life role at Mercer is Innovation Leader for the MOT. Yvonne served as an Advisory Board International region, leading design projects member of TransformAgeing, has now been in the areas of Health, Wealth and Careers. At appointed to the Healthy Ageing Advisory present, she is leading major global projects Group working on the UK Governmentʼs around flexible ways to source, manage, Ageing Society Grand Challenge. She motivate and reskill future workforces, as well supports a number of other specialist bodies as co-leading Mercerʼs Next Age initiative examining the demographic impact on focussed on longevity. workers, work and the workplace.

Yvonne recently Co-Chaired the UK She is a Fellow of The Pensions Management Government Department for Work and Institute and a previous author of their Pensions Fuller Working Lives Business International Diploma syllabus. Yvonne has Strategy Group, working with employers to MastersDegrees inPsychology and Business recruit, retain and retrain older workers. Her Research, and in her spare time holds both firstbook, The New Rules ofLiving Longer,was Trustee and Director roles in Creative Arts published in November 2015,with a foreword organisations.

www.thelongevityforum.com The Longevity Forum 2019 STRATEGICPARTNERS STRATEGICPARTNERS

Barclays Private Bank Hill Dickinson

At Barclays Private Bank, we have the Chief Scientific Officer at SENS Research Hill Dickinson LLP is a leading and award- We also help clients navigate a legal and scale, connectivity and determination to Foundation, to understand the implications winning international commercial law firm regulatory landscape that is continuously help you make the most of burgeoning of ground breaking new developments in with offices in the UK, mainland Europe and evolving in response to innovation as well as developments. biotechnology. Asia. societal and ethical challenges.

We recognise that breakthroughs in Barclays Private Bank are proud to sponsor Our Life Sciences team provides practical, Our interdisciplinary team blends insight and bioscience could increase life expectancies the Longevity Forum 2019 and believe that commercial legal advice to companies at pragmatism to provide high-quality, trusted and help people live fitter,healthier lives for our shared goals to support healthy longevity all stages of development, from start-upto advice to some of the worldʼs leading life muchlonger than we ever thoughtpossible. and overall productivity will drive innovation established multinational. sciences companies. Our Beyond 100 series investigates the and investment within this field. economic and societal impact of longevity We support clients from an idea in a lab, to Areas of expertise in which we work include to help you understand how longer lifespans Ourhighlyfocused andcollaborative approach helping incorporate the company, raising pharma, biotech, healthtech, medical could transform the next generation, and to growth draws on a wide range of advisors capital, protecting and licensing intellectual cannabis, cell and gene therapies, genomics, what it could mean for you, your family and and specialist services and at the heart of this property,signing strategic partnerships and, IVF and embryo research. your portfolio. relationship is a dedicated Private Banker. ultimately, commercialising life-changing treatments and technologies. www.hilldickinson.com In the white paper report, video and Our Chief Market Strategist, Gerald Moser, podcast we spoke to world-leadingexperts will be joining Andrew Scott on the Longevity including Lynda Gratton, co-author of Dividend panel to discuss the challenges and the 100 year life and Dr Aubrey de Grey, opportunities that come with longer lifespans.

www.thelongevityforum.com The Longevity Forum 2019 STRATEGICPARTNERS THE LONGEVITY FORUMSUPPORTERS

Juvenescence L imited

Extending Healthy Lifespan

Developing therapies to treat diseasesof ageing and increase human longevity. Background Zincʼs Third Mission; Later life

Juvenescence develops therapies that The Juvenescence team comprises proven Zinc builds new companies that tackle The mission we have selected for our third will enable people worldwide to live andseasoned pharmaceuticalindustryexperts important societal issues. We do this programme, beginning September 30th, longer, healthier lives. We actively look for covering drug research and development, through a 9-month,full-time programme for 2019, is to add more years of high quality to scientific founders probing exciting areas strategy, structure, commercialization and 50 creative, entrepreneurial individualswho later life. of ageing biology, and work with leading finance. The team members, located across cometogethertocreate anew businessfrom research institutionsto create jointventures the US and the UK, design the R&D strategy scratch. They build scalable products and We know that, globally, the over-60s are combining their IP and our resources. and go/no-go experiments, to mitigate the services that target millions of customers, expected to spend $15 trillion annually by risk in each of our programs. based on the best social science research, 2020. Yet, too often, their needs are ignored, We are very active partnersinthecompanies exponential technologies and creative underserved or badly-designed-forby youth- we create. In addition to providing financial A key element within the Juvenescence design. Each of our programmes focuses obsessed businesses andunresponsivepublic support, we use our extensive drug ecosystem is our use of artificial intelligence on one ʻmissionʼ.Our previous two missions services. Weʼve identified 10 opportunity development expertise to give ground- and machine learning techniques to have focused on improving womenʼs areas, including assistive technology, disease breaking science the best opportunity of discover and develop new drugs, working mental health, and unlocking opportunities prevention and financial services, which we achieving value-driving inflection points in conjunction with our partners, Insilico for people who live in places hard-hit by believe contain importantand fertile areas for for targeted programmes, always with the Medicine and Netramark. automation and globalisation. We have a new products and services with the potential goal of serving unmet patient need. Our live portfolio of >20 companies that have to improve the quality of later life for millions. pipeline of companies allows for flexible We have also partnered with leading emerged from these two programmes. Weʼre excitedto have selected the nextcohort financing of individual opportunities, easy research institutions across the globe, like of 50 Founders, from >600applications. They pipeline management, and the ability to exit the Buck Institute for Research on Aging. The 50 entrepreneurs who join our are an interesting & talented mix, including via licensing, sale of underlying assets and Napa Therapeutics and BHB Therapeutics, programmes are a motivated, talented and robotics engineers, former CCG leaders, royalties. both Buck spinouts, were capitalized by diverse bunch. For each programme, we doctors, creative designers, management Juvenescence. are also extremely fortunate to have the consultants, etc. Over the next nine months, Juvenescence has raised USD $165million support of a wide community of experts, they will create and test a range of innovative to-dateto create joint ventures and build an This ecosystem will allow our pipeline whom we call ʻVisiting Fellowsʼ. Our productsand services across a range of areas ecosystem of seasoned drug developers companies to cross-pollinateand collaborate, Fellows network represents an incredible of relevance to later life. to support scientists, universities, and adding further value to each of the individual breadth and depth of expertise, including institutions specializing in ageing, opportunities. in technology, design, business, health, For more information about the programme , and the diseases of ageing. education, employment, and more. and ways to get involved (e.g. as a potential www.juvenescence.ltd partner,investor, collaborator), visit our website www.zinc.vc or contact [email protected].

www.thelongevityforum.com The Longevity Forum 2019 THE LONGEVITY FORUM SUPPORTERS

FOR MOREINFORMATION,PLEASECONTACT

[email protected] WWW.THELONGEVITYFORUM.COM

@LONGEVITY_FORUM THELONGEVITYFORUM

STRATEGICPARTNERS 2019